CREO MEDICAL GROUP PLC
Get an alert when CREO MEDICAL GROUP PLC files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-06-30 (in 1mo)
Last filed for 2024-12-31
Confirmation statement due
2026-09-25 (in 4mo)
Last made up 2025-09-11
Watchouts
Cash
£9M
+190% vs 2023
Net assets
£42M
-29.1% vs 2023
Employees
129
-55.1% vs 2023
Profit before tax
-£2M
-483.3% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
3 officer resignations in last 12 months
Multiple officers have left the board recently — see the People section for who.
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £30,800,000 | £30,700,000 | |
| Operating profit | £600,000 | -£2,100,000 | |
| Profit before tax | £600,000 | -£2,300,000 | |
| Net profit | -£21,700,000 | -£28,700,000 | |
| Cash | £3,000,000 | £8,700,000 | |
| Total assets less current liabilities | £62,400,000 | £44,800,000 | |
| Net assets | £59,800,000 | £42,400,000 | |
| Equity | £59,800,000 | £42,400,000 | |
| Average employees | 287 | 129 | |
| Wages | £12,800,000 | £18,400,000 | |
| Directors' remuneration | £3,042,236 | £1,286,477 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
-0.3%
£30,800,000 £30,700,000
-
Cash
+190%
£3,000,000 £8,700,000
-
Net assets
-29.1%
£59,800,000 £42,400,000
-
Employees
-55.1%
287 129
-
Operating profit
-450%
£600,000 -£2,100,000
-
Profit before tax
-483.3%
£600,000 -£2,300,000
-
Wages
+43.8%
£12,800,000 £18,400,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 1.9% | -6.8% | |
| Net margin | -70.5% | -93.5% | |
| Return on capital employed | 1.0% | -4.7% | |
| Gearing (liabilities / total assets) | 21.9% | 28.1% | |
| Current ratio | 0.61x | 3.27x | |
| Interest cover | 3.00x | -5.25x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- CREO MEDICAL GROUP PLC 2016-11-28 → present
- CREO MEDICAL GROUP LIMITED 2016-09-12 → 2016-11-28
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- RSM UK Audit LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Based on the above, the Directors are satisfied that the Group and Company will have sufficient funds to meet their liabilities as they fall due for the going concern period and have therefore prepared the financial statements on a going concern basis.”
Group structure
- CREO MEDICAL GROUP PLC · parent
- Creo Medical Limited 100%
- Creo Medical Innovations Limited 100%
- Creo Medical SLU 100%
- Creo Medical S.L.U. 100%
- Creo Medical SASU 100%
- Creo Medical UK Limited 100%
- Creo Medical GmbH 100%
- Premier Endoscopy Limited 100%
- Wiest Uropower Limited 100%
- Boucart Medical SRL 100%
- Aber Electronics Limited 100%
Significant events
- “Total group revenue of £30.7m with £4.0m from continuing operations and £26.7m from discontinued operations, following the sale of Creo Medical Europe. Commercial roll out of Speedboat UltraSlim during a strong overbroad and 74% increase in Creo Core Technology sales to FY24.”
- “Cost reductions of c.£5.0m (annualised basis) on continuing operations made during H2 24 with the full c.£5.0m benefit to be realised in FY25.”
- “£12m before expenses raised through a placing and open offer in October 2024.”
- “Strategic partnership with Micro-Tech (Nanjing) Co. Ltd and sale of 51% of Creo Medical Europe, realising approximately £30m net cash to strengthen balance sheet gross period with a £30m investment asset held on the balance sheet, providing future balance sheet strength.”
- “Remaining 49% stake in Creo Medical Europe to provide cash inflows, going forwards, via an ongoing share of profits.”
- “Board refresh with a new Chairman and additional NEDs, bringing external strength, industry expertise and experience to the team.”
- “Amendment to the collaboration agreement with Intuitive Surgical and controlled market release of MicroBlade Flex, increasing the number of sites able to undertake combined robotic diagnostic and ablation procedures.”
- “Significant progress in roll out of Creo's Core Technology with over 5,000 procedures performed globally to date with Speedboat UltraSlim being used in over 3,500 resection procedures in its first year on the market.”
- “Multiple upper and lower GI procedures performed with Speedboat UltraSlim further enhanced by the launch of Speedboat Notch post period end in April 2025.”
- “NHS Supply Chain case study published setting out significant cash and operational savings from the use of Speedboat Submucosal Dissection ("SSD") procedures.”
- “King's Award for Enterprise received for Creo's Speedboat technology.”
- “World's first robotic-guided microwave ablation of lung tissue in the clinic using a diagnostic procedure performed using MicroBlade Flex.”
- “Launch of SpydrBlade Flex following CE marking during the year.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 5 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CRAVEN, Richard Gary | Secretary | 2024-07-01 | — | — |
| BOUCHER, Brent Jay | Director | 2024-07-01 | Jul 1967 | American |
| CANTU, Ivonne | Director | 2020-02-01 | Jul 1968 | Mexican |
| CROFTON, Kevin Timothy | Director | 2024-07-01 | Mar 1961 | American,British |
| GULLIFORD, Craig Jonathan | Director | 2016-09-12 | May 1970 | British |
| REES, Richard John | Director | 2016-09-12 | May 1976 | Welsh |
Show 5 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| REES, Richard | Secretary | 2016-09-12 | 2024-07-01 |
| BRADSHAW, John | Director | 2016-12-08 | 2025-05-22 |
| HANCOCK, Christopher Paul, Professor | Director | 2016-09-12 | 2025-06-26 |
| SPICER, Charles Alexander Evan, Dr | Director | 2016-12-05 | 2024-07-01 |
| WOODS, David Gerard | Director | 2016-11-30 | 2025-06-26 |
Ownership
Persons with significant control
Filing timeline
Last 20 of 115 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-07-02 RESOLUTIONS Resolution
- 2024-10-27 RESOLUTIONS Resolution
- 2024-07-01 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-09-16 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-07-02 | RESOLUTIONS | resolution | Resolution | |
| 2025-06-27 | TM01 | officers | Termination director company with name termination date | |
| 2025-06-26 | TM01 | officers | Termination director company with name termination date | |
| 2025-06-11 | AA | accounts | Accounts with accounts type group | |
| 2025-05-23 | TM01 | officers | Termination director company with name termination date | |
| 2025-01-22 | SH01 | capital | Capital allotment shares | |
| 2024-10-27 | RESOLUTIONS | resolution | Resolution | |
| 2024-10-22 | SH01 | capital | Capital allotment shares | |
| 2024-09-13 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-08-06 | SH01 | capital | Capital allotment shares | |
| 2024-07-02 | TM02 | officers | Termination secretary company with name termination date | |
| 2024-07-02 | TM01 | officers | Termination director company with name termination date | |
| 2024-07-02 | AP01 | officers | Appoint person director company with name date | |
| 2024-07-02 | AP03 | officers | Appoint person secretary company with name date | |
| 2024-07-01 | AP01 | officers | Appoint person director company with name date | |
| 2024-07-01 | RESOLUTIONS | resolution | Resolution | |
| 2024-06-03 | AA | accounts | Accounts with accounts type group | |
| 2024-01-22 | SH01 | capital | Capital allotment shares | |
| 2023-09-13 | CS01 | confirmation-statement | Confirmation statement with updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 6
- Capital events
- 3
- Officers appointed
- 0
- Officers resigned
- 3
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.